A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

December 1, 2025

Conditions
HR+/HER2- Early Breast Cancer
Interventions
DRUG

Fuzaparib

"Folfoxapril:~Take 2 times a day (once in the morning and once in the evening, 150mg in the morning and 100mg in the evening; vice versa is also acceptable). Each 3-week period constitutes one cycle. For the first to fourth cycles, a total of 4 cycles are required."

OTHER

standard chemotherapy

standard chemotherapy

Trial Locations (1)

710032

RECRUITING

Xijing hospital, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER